Regeneron Stock: Valuation Now Demands More Growth

(12min)

Summary

  • Regeneron Pharmaceuticals stock reached new all-time highs this month, driven by the Eylea franchise returning to growth in the second quarter, and despite minor regulatory setbacks for the oncology pipeline.
  • Dupixent and Libtayo delivered strong growth in the second quarter.
  • European Commission approvals of Dupixent for COPD and odronextamab for two hematologic malignancies offer some consolation after FDA delays and rejections for the same applications.
  • REGN stock's valuation demands more growth, and I expect Regeneron to deliver it with its expanding pipeline, and through business development.
  • Looking for a helping hand in the market? Members of Growth Stock Forum get exclusive ideas and guidance to navigate any climate. Learn More »

A rising bar graph made of bricks supporting a zigzag line

Richard Drury

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) reached new all-time highs this month. This was driven by the Eylea franchise returning to growth in the second quarter, and despite minor regulatory setbacks for the oncology side of the pipeline. These involved

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button. And to go deeper, sign up for a free trial to Growth Stock Forum.

This article was written by

9.14K Followers

ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential and calculates ideas in large part based on best risk-adjusted returns.

He leads the investing group Growth Stock Forum which features: a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks that are expected to perform well in the current calendar year, trading ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About REGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on REGN

Related Stocks

SymbolLast Price% Chg
REGN
--